Celyad Oncology Reports First Half Year 2025 Financial Results

Regulatory News:

Celyad Oncology (Euronext: CYAD) (the “Company”), today announced its financial results for the first half year 2025 ended June 30, 2025.

First Half 2025 financial review

As of June 30, 2025, the Company’s Treasury position amounted to €0.8 million.

After due consideration of detailed budgets and estimated cash flow forecasts for the years 2025 and 2026, the Company projects that its existing cash and cash equivalents will be sufficient to fund its estimated operating and capital expenditures into the fourth quarter of 2025.

Key financial figures for first half 2025, compared with the first half of 2024 and full year 2024, are summarized below:

Selected key financial figures (€ millions)	Half Year 30 June 2025	Half Year 30 June 2024	Full Year 31 December 2024
Revenue	-	-	0.2
Research and development expenses	(2.1)	(1.5)	(3.2)
General and administrative expenses	(1.7)	(1.7)	(3.2)
Other income/(expenses)	0.1	0.2	0.4
Operating loss	(3.7)	(3.1)	(5.9)
Loss for the period/year	(3.7)	(3.0)	(5.9)
Net cash used in operations	(3.3)	(2.8)	(5.7)
Cash and cash equivalents	0.8	6.2	4.2

Research and Development (R&D) expenses were €2.1 million in June 2025 as compared to €1.5 million during the same period in 2024, an increase of €0.6 million. The increase in the Company’s R&D expenses was primarily driven by the increase of the IP costs related to the licensing activities as well as the increase of the expenses linked to the redevelopment of the catheter.